Buy 3SBio Up to $10

3SBio Inc. (SSRX - Snapshot Report) is a China-based biotech company focused on developing and marketing therapeutics for nephrology, oncology and cancer supportive care. The company's flagship product EPIAO is the number 1 brand in China's EPO [erythropoietin] market.

Its second lead product TPIAO has gained rapid physician acceptance for thrombocytopenia and is making a meaningful contribution to the company's top line growth. Recent deal with US-based AMAG Pharmaceuticals Inc. (AMAG - Snapshot Report) will boost its expansion into IV Iron market.

We believe shares of 3SBio are undervalued and are attractive at current levels. We maintain a Buy rating with a price target of $10.